Merck & Co Inc (MRK) — Stock Analysis & Corporate History

Beyond the Pill: The Three-Century Odyssey of Merck & Co.

Picture a world before electricity, where the concept of modern medicine was nothing more than an apothecary’s dream. In 1668, a man named Friedrich Jacob Merck purchased a small shop called the Engel-Apotheke (Angel Pharmacy) in Darmstadt, Germany.

He could never have imagined that his humble storefront would plant the seed for a multi-century dynasty, eventually evolving into Merck & Co., Inc., a $300 billion pharmaceutical titan that shapes both global health and the modern macroeconomic landscape.

Today, Merck & Co. is a household name, but its journey from a 17th-century German pharmacy to a pillar of the American economy is a saga of geopolitical fracture, groundbreaking scientific triumphs, and the complex realities of the modern biopharmaceutical industry.

The Transatlantic Fracture: A Tale of Two Mercks

To understand Merck & Co. today, one must uncover a rare and precious piece of corporate history: the great split. The Merck family successfully ran their chemical and pharmaceutical business in Europe for generations. In 1891, George Merck traveled across the Atlantic to bring the family’s scientific rigor to the United States, establishing Merck & Co. in New York.

However, the outbreak of World War I violently fractured this transatlantic bond. In 1917, as the U.S. entered the war, the American government confiscated Merck's U.S. operations under the Alien Property Custodian. In a display of bold business acumen, George Merck secured financial backing to buy back the company stock at a public auction in 1919 for $3.75 million, permanently severing the American branch from its German parent company. Because of this historical geopolitical split, the two companies are entirely separate today. The U.S. company operates as Merck & Co. in the United States and Canada, but is known globally as MSD (Merck Sharp & Dohme). Meanwhile, the original German entity, Merck KGaA, operates globally but must use the name EMD in North America.

A Legacy of Rare Feats: From the Manhattan Project to River Blindness

As an independent American company, Merck & Co. transitioned from a fine chemicals distributor to an architectural force in modern medicine. During World War II, the company's research labs were instrumental in the mass production of penicillin for the Allied war effort. In a lesser-known but fascinating historical footnote, Merck even utilized its advanced chemical capabilities to produce uranium compounds for the highly secretive Manhattan Project.

It was during this transformative era that George W. Merck, the founder's son, embedded a philosophical north star into the company's culture. In 1950, he famously declared: “We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear”.

This ethos was put to the ultimate test in the 1980s with a drug called Mectizan. Merck scientists had stumbled upon a treatment that effectively cured river blindness (onchocerciasis), a devastating parasitic disease ravaging remote communities in Africa. Realizing that the populations who desperately needed the drug had no money to buy it, Merck made an unprecedented decision in 1987: they would donate Mectizan for free, "as much as needed, for as long as needed". To date, the company has donated over 5 billion treatments, an act of corporate philanthropy that has virtually eliminated the disease in several nations.

The Economic Engine: Financial Might and Global Contribution

Fast forward to the present day, and Merck & Co. is a staggering economic engine. In 2025, the company reported $65.0 billion in total worldwide sales. This financial muscle does not just sit in corporate vaults; it actively fuels the global "innovation economy."

Merck’s commitment to scientific discovery requires a massive reinvestment of capital. In 2024, the company spent $17.9 billion on research and development (R&D), and followed it up with another $15.8 billion in 2025. This represents one of the highest R&D reinvestment rates in any industrial sector.

Beyond the laboratory, Merck is a massive job creator and community builder. The company employs approximately 75,000 people globally. Furthermore, its sprawling global supply chain heavily supports smaller economies; in 2024 alone, Merck spent $4.0 billion with small and diverse Tier 1 and Tier 2 suppliers, sustaining over 43,000 jobs within its extended network. From high-skill research positions to extensive manufacturing networks across 120 countries, Merck’s operations are a vital artery for the global economy.

Anchoring the Dow Jones Industrial Average

Because of its immense size and stability, Merck is a crucial component of the Dow Jones Industrial Average (DJIA), having been added to the prestigious index in June 1979. To understand Merck's impact on the stock market, one must look at how the Dow is structured.

Unlike the S&P 500, which is weighted by total market capitalization, the Dow is a price-weighted index. This means a company's influence on the index's movement is dictated entirely by its individual share price. Trading around the $120 mark, Merck holds a weighting of approximately 1.13% to 1.6% in the Dow.

For investors, Merck is the ultimate defensive staple. It boasts a remarkably low Beta of 0.26, indicating that its stock is significantly less volatile than the broader market. When macroeconomic shocks, geopolitical crises, or tech-bubble bursts send the markets into a tailspin, pharmaceutical giants like Merck act as an anchor, stabilizing the Dow and protecting institutional and retail portfolios while providing a reliable dividend yield of around 2.8%.

The Crown Jewels: Keytruda and the Animal Health Hedge

How does Merck generate such monumental revenue today? The answer lies largely in its oncology franchise, driven by the revolutionary cancer drug Keytruda (pembrolizumab).

Keytruda generated an astonishing $31.68 billion in sales in 2025, accounting for nearly half of the company's total revenue. It is an immuno-therapeutic marvel known as a checkpoint inhibitor. Cancer cells often use specific proteins (like PD-L1) to effectively "blind" the human immune system. Keytruda blocks this interaction, stripping away the tumor's invisibility cloak and reactivating the patient's own T-cells to hunt down and destroy the cancer.

But Merck is not a one-trick pony. It holds a dominant position in vaccines with Gardasil, which protects against the human papillomavirus (HPV). Additionally, the company operates a highly lucrative Animal Health division, which generated $6.35 billion in 2025. Selling veterinary pharmaceuticals and popular companion animal products like the Bravecto flea and tick treatment, this division provides a critical financial hedge. Animal health products generally have longer lifecycles and are immune to the dramatic patent cliffs that plague human drugs, adding a layer of bulletproof stability to Merck’s balance sheet.

A Dark Chapter: The Vioxx Crisis

To provide a truly objective look at Merck, one must also examine its darkest hour. In 1994, the company broke from its tradition of being led by scientists and hired Ray Gilmartin, a Harvard-trained businessman, as CEO. Critics argue that under this new leadership, the company's moral compass—which historically pointed toward health and safety—began to point too heavily toward the dollar sign.

In 1999, Merck launched Vioxx, a blockbuster drug for chronic pain and arthritis. However, scientific data soon linked the drug to a significantly increased risk of heart attacks and strokes. Despite internal warnings, the company delayed action until a massive global recall was finally initiated in 2004. The fallout was catastrophic. Merck faced a tidal wave of litigation, ultimately agreeing to pay nearly $4.85 billion to settle tens of thousands of patient lawsuits, alongside almost $1 billion in government fines for illegal marketing. The Vioxx scandal remains a stark reminder of the devastating human and financial costs that occur when a biopharmaceutical giant prioritizes immediate profits over rigorous scientific safety.

Navigating the Future: Patent Cliffs and the IRA

Today, Merck stands at a critical strategic crossroads. The company is preparing for a looming "patent cliff" as Keytruda is expected to lose its market exclusivity and face biosimilar competition around 2028 to 2029.

Concurrently, the regulatory landscape in the United States has shifted dramatically with the implementation of the Inflation Reduction Act (IRA). For the first time, the U.S. government has the power to negotiate and set prices for top-selling Medicare drugs. Several of Merck's key products, including the diabetes drugs Januvia and Janumet, and the cancer drug Lenvima, have already been selected for government price setting. Merck anticipates that Keytruda will also be subjected to government price setting by 2029, which will materially reduce its U.S. revenues.

To survive and thrive post-Keytruda, Merck is executing an aggressive diversification strategy. The company recently launched Winrevair, a breakthrough treatment for pulmonary arterial hypertension, which rapidly generated $1.44 billion in its first full year on the market in 2025. Merck is also actively acquiring innovative biotech firms, such as the $1.2 billion acquisition of EyeBio to expand into ophthalmology, and is investing heavily in artificial intelligence to streamline drug discovery and "smartfacturing".

Conclusion

Merck & Co. is far more than a corporate entity; it is a foundational pillar of the modern biopharmaceutical paradigm. From its ancestral roots in a 17th-century German pharmacy to its role as a stabilizer of the Dow Jones Industrial Average, the company’s trajectory mirrors the evolution of global healthcare. Despite facing monumental challenges—from the geopolitical fracture of World War I to the self-inflicted wounds of the Vioxx crisis, and the modern hurdles of the Inflation Reduction Act—Merck continues to reinvent itself. By blending its three-century legacy of rigorous science with massive economic investments, Merck & Co. remains an indispensable force in the ongoing quest to save and improve human life.